IOncology

In a special interview at the 20th International Society for Diseases of the Esophagus (ISDE) conference, Dr. Jens Hoeppner from Bielefeld University in Germany shared his insights on the FLOT regimen's clinical benefits over the CROSS regimen in the treatment of locally advanced resectable esophageal adenocarcinoma. He also discussed the potential integration of immunotherapy and the 'watch and wait' strategy in future treatments.

In a recent interview, Dr. Virginia Kaklamani discussed the rapidly advancing landscape of hormone receptor-positive breast cancer treatments. With the emergence of novel medications like CDK4-6 inhibitors, oral SERDs, and PI3K/AKT pathway inhibitors, she emphasized the need for NGS testing to guide treatment decisions. Dr. Kaklamani highlighted the unique efficacy and safety profiles of alpelisib, inovolacib, and capivacertib, and provided insights on selecting the most suitable therapy based on specific genetic mutations.

The 27th National Conference on Clinical Oncology and the 2024 CSCO Annual Meeting, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, was held from September 25 to 29, 2024, in Xiamen. During the conference, several forums on lung cancer covered cutting-edge research and developments in the field. During the event, Oncology Frontier invited Dr. Yilong Wu from Guangdong Provincial People’s Hospital to share his insights on making targeted therapy decisions for patients with EGFR-mutant non-small cell lung cancer (NSCLC).

The 27th National Clinical Oncology Conference and 2024 CSCO Academic Conference, co-hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing CISCO Clinical Oncology Research Foundation, took place in Xiamen from September 25 to 29, 2024. During this event, Dr. Tetsuya Mitsudomi, who has led several large-scale immunotherapy clinical trials, gave an academic report on the latest progress in immunotherapy for NSCLC. Oncology Frontier invited Dr. Baohui Han from Shanghai Chest Hospital to have an in-depth conversation with Dr. Tetsuya Mitsudomi from Kindai University School of Medicine in Japan. They shared insights on decision-making strategies for perioperative treatment, prognostic biomarkers, and managing adverse events in NSCLC immunotherapy.

Although melanoma has a relatively low incidence among malignant tumors, its hidden onset and high malignancy make it a formidable disease. In recent years, targeted and immunotherapy treatments for solid tumors have developed rapidly, many of which began with melanoma and later extended to other cancers. However, there are significant biological differences between melanoma in Chinese and Western patients, necessitating the development of treatment protocols and standards tailored to Chinese and Asian patients. At the 2024 CSCO Conference, Dr. Jun Guo from Peking University Cancer Hospital, Dr. Xiaohui Niu from Beijing Jishuitan Hospital/National Center for Orthopedics, Dr. Di Wu from The First Bethune Hospital of Jilin University, and Dr. Lu Si from Peking University Cancer Hospital shared insights into the journey of melanoma diagnosis and treatment in China. They also reflected on the efforts of the CSCO Melanoma Expert Committee in establishing standardized treatment guidelines tailored to China’s needs.

The 2024 CSCO Ovarian Cancer Session covered various topics, including surgical treatment for ovarian cancer, drug therapy for advanced-stage patients, and data from novel drug research. Dr. Lingying Wu from the Cancer Hospital Chinese Academy of Medical Sciences chaired the session, where Dr. Oliver Dorigo from Stanford University delivered a report on “Cellular Therapy for Ovarian Cancer,” and Dr. Jianyu Rao from University of California, Los Angeles(UCLA) discussed “Precision Treatment Strategies for Ovarian Cancer.” After the session, the three experts participated in Oncology Frontier’s “CSCO International Perspectives” column, engaging in an in-depth discussion on cellular therapy and precision treatment strategies for ovarian cancer.

At the 2024 ESMO Conference, the Phase 1a/1b study of the novel drug GQ1005, led by Dr. Biyun Wang from Fudan University Shanghai Cancer Center, was showcased as a poster presentation, garnering significant attention. This study not only confirmed the efficacy and safety of GQ1005 in HER2-low breast cancer and HER2-positive gastric cancer but also laid a solid foundation for its future clinical applications. We invited Dr. Biyun Wang to delve into the background, study design, preliminary efficacy, and safety data of the GQ1005 Phase 1a/1b study, while also discussing its promising future in combination therapies.

The 2024 European Society for Medical Oncology (ESMO) Congress took place in Barcelona, Spain, from September 13 to 17. During the event, Dr. Miaoyan Wei from Fudan University Shanghai Cancer Center presented the results of an open-label, single-arm, single-center Phase II clinical trial exploring the use of fruquintinib combined with nab-paclitaxel and gemcitabine (AG) as a first-line treatment for liver metastases in pancreatic ductal adenocarcinoma (PDAC). This study was featured in the poster session (Abstract #1529P). In this interview, Dr. Wei provides an in-depth analysis of the study's findings.

The 2024 World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer (IASLC), is currently in full swing in San Diego, USA.  Oncology Frontier invited domestic lung cancer experts to analyze key research data from the conference. This article presents Dr. Shengxiang Ren's review of the NeoCOAST-2 study results (Abstract PL02.07) from Shanghai Pulmonary Hospital.

The 2024 European Society for Medical Oncology (ESMO) Annual Congress was held from September 13 to 17 in Barcelona, Spain, where multiple advancements in lung cancer research were presented. Dr. Jonathan D. Spicer from the McGill University Health Centre in Montreal, Canada, shared the updated clinical data from the CheckMate 77T study. During the congress, Oncology Frontier interviewed Professor Spicer, who provided insights on the updated data and discussed how to choose between neoadjuvant therapy, adjuvant therapy, and perioperative strategies in resectable non-small cell lung cancer (NSCLC).